	US 12,226,377 B2
	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
Julien Grassot, Lyons (FR); Cendrine Grangeon, Lyons (FR); and Jordan Dubow, Chicago, IL (US)
Assigned to Flamel Ireland Limited, Dublin (IE)
Filed by Flamel Ireland Limited, Dublin (IE)
Filed on Jun. 10, 2022, as Appl. No. 17/837,740.
Application 17/837,740 is a continuation of application No. 16/804,966, filed on Feb. 28, 2020, granted, now 11,400,065.
Claims priority of provisional application 62/857,008, filed on Jun. 4, 2019.
Claims priority of provisional application 62/812,699, filed on Mar. 1, 2019.
Prior Publication US 2022/0313635 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/19 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/19 (2013.01) [A61K 9/0053 (2013.01); A61K 9/009 (2013.01); A61K 9/0095 (2013.01)]

1 Claim

1. An oral pharmaceutical composition for the treatment of a disorder treatable with gamma-hydroxybutyrate in a human subject in need thereof, the pharmaceutical composition comprising gamma-hydroxybutyrate in a unit dose, wherein absorption of the gamma-hydroxybutyrate in the gastro-intestinal tract is not substantially changed by the presence of food.